22 Apr 2022 07:00
22 April 2022
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Update re admission of Subscription Shares
Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, announces that further to its announcements on 12 April 2022 and 19 April 2022, application has been made for 400,000 Subscription Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on or around 27 April 2022.
Second Admission will now comprise 3,540,000 Subscription Shares and is expected to take place on or around 10 May 2022.
Total Voting Rights
Following Admission on 27 April 2022, the Company's enlarged issued share capital will comprise 466,612,211 Ordinary Shares, of 25 pence each ("Ordinary Shares"). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights on 27 April 2022 will be 466,612,211. Upon Second Admission, the Company's enlarged issued share capital will comprise 470,152,211 Ordinary Shares, of 25 pence each and the total number of Ordinary Shares in the Company with voting rights on Second Admission will be 470,152,211. The aforementioned figures may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement shall have the same meaning as in the announcement of 12 April 2022 unless otherwise defined herein.
- ENDS -
Advanced Oncotherapy plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO | |
Allenby Capital Limited (Nomad and Joint Broker) | |
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking) | Tel: +44 (0) 20 3328 5656 |
SI Capital Ltd (Joint Broker) | |
Nick Emerson | Tel: +44 (0) 1483 413 500 |
Jon Levinson | Tel: +44 (0) 20 3871 4066 |
FTI Consulting (Financial PR & IR) | advancedoncotherapy@fticonsulting.com |
Simon Conway / Rob Winder | Tel: +44 (0) 20 3727 1000 |
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.